Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug

Hope Medicine Inc. has officially commenced the Phase III clinical trial for HMI-115, marking a significant advancement in the treatment of endometriosis. The first patient was recently dosed at Peking Union Medical College Hospital, a leading clinical site in China. This multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of HMI-115 in managing moderate-to-severe pain associated with endometriosis over a 24-week treatment period. As a first-in-class monoclonal antibody with global rights, HMI-115 represents a potential paradigm shift in women's health, particularly as it is currently the only non-hormonal therapy globally to reach this advanced stage of clinical development.

The significance of this milestone cannot be overstated within the context of the current endometriosis treatment landscape. For decades, the standard of care has relied heavily on hormonal therapies, such as GnRH agonists and antagonists, which work by suppressing estrogen levels. While effective for pain management, these treatments often induce a state of pseudo-menopause, leading to debilitating side effects including bone mineral density loss, hot flashes, and mood swings. HMI-115 offers a distinct mechanism of action that targets the prolactin receptor pathway, providing a non-hormonal alternative that aims to alleviate pain without disrupting the endocrine balance of the patient.

“

Food and Drug Administration (FDA) previously granted HMI-115 Fast Track Designation, while the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) awarded it Breakthrough Therapy Designation.

Regulatory bodies have already signaled the high potential of this therapeutic candidate. The U.S. Food and Drug Administration (FDA) previously granted HMI-115 Fast Track Designation, while the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) awarded it Breakthrough Therapy Designation. These accolades are underpinned by robust Phase II data, recently published in The Lancet Obstetrics, Gynaecology, & Women’s Health. The Phase II results demonstrated statistically significant improvements in pain scores compared to placebo, crucially without the menopausal side effects that typically limit the long-term use of existing hormonal treatments.